Medicare Advantage plans and commercial payers might follow CMS' lead in cutting pay to hospitals for drugs bought through the 340B drug discount program, lobbyists say. A spokesperson for 340B Health says there could be broader ramifications from CMS' policy than the agency considered, and those ramifications could undermine the drug discount program. CMS on Wednesday (Nov. 1) announced plans to cut hospital reimbursement for Part B drugs purchased through 340B by nearly 30 percent, from 106 percent of average...